Cat. No. 1487
Alternative Name: AYPGKF-NH2
Biological ActivitySelective PAR4 receptor agonist peptide. Stimulates platelet aggregation in vitro (EC50 = 15 μM). Exhibits an increase in paw thickness in the paw edema inflammation model in vivo.
(Modifications: Phe-6 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Hollenburg et al (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br.J.Pharmacol. 143 443. PMID: 15451771.
Hollenberg and Saifeddine (2001) Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can.J.Physiol.Pharmacol. 79 439. PMID: 11405248.
Faruqi et al (2000) Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. J.Biol.Chem. 275 19728. PMID: 10779527.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AY-NH2 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AY-NH2, supplier, selective, PAR4, agonists, receptors, protease-activated, proteinase-activated, peptide, Tocris Bioscience, Protease-Activated Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonistNeuropeptide S (Mouse)
Potent endogenous neuropeptide S receptor (NPSR) agonistML 382
MrgX1 (SNSR4) positive allosteric modulatorK-(D-1-Nal)-FwLL-NH2
High affinity and potent ghrelin receptor inverse agonistNeuropeptide S (Rat)
Potent endogenous neuropeptide S receptor agonistNeuropeptide S (human)
Potent endogenous neuropeptide S receptor agonist
October 30 - November 3, 2016
Boston, MA, USA